Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

3M Seeking To Divest Pharma Business

This article was originally published in The Pink Sheet Daily

  • News
  • Kathleen Michael

Executive Summary

Firm’s key products include the oncologic cream Aldara, obesity drug Duromine and bacterial vaginosis gel MetroGel-Vaginal.

You may also be interested in...



Newcomer Graceway Acquires 3M’s American Pharmaceutical Business

Headed by former King chief Gregory, the nine-month-old Tennessee pharma gains access to 3M’s immune response modifier platform on which to build a portfolio.

Newcomer Graceway Acquires 3M’s American Pharmaceutical Business

Headed by former King chief Gregory, the nine-month-old Tennessee pharma gains access to 3M’s immune response modifier platform on which to build a portfolio.

QLT MetroGel Generic Will Launch In The U.S. Under Partnership With Sandoz

FDA approves QLT’s metronidazole vaginal gel 0.75% as first generic version of 3M’s MetroGel.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Simplified Clinical Trial Transparency Rules To Go Live In The EU In June

Changes To EU Pharma Reform: More Questions Than Answers?

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

See All
UsernamePublicRestriction

Register

PS064089

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By